Brought to you by 
Aspire Capital commits to buying up to $30mm of NuPathe common stock
16 Aug 2011
Executive Summary
Over the next two years, Aspire Capital Fund LLC has committed to buy up to $30mm (as much as 2.9mm shares, but not to exceed 19.9% shares outstanding) in specialty neurology pharma NuPathe Inc.’s common stock. Aspire has initially purchased 70.7k shares at $7.07 (market average) for a total of $500k out of the $30mm credit facility. (In consideration for entering the agreement, NuPathe issued 84.9k shares to Aspire.)
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Drug Delivery
- Controlled Release
- Transdermal
Deal Status
- Final
Deal Type
-
Financing
- Other
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Aspire Capital commits to buying up to $30mm of NuPathe common stock
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice